1,721,009 research outputs found
Atorvastatin treatment increases circulating endothelial progenitor cells in patients undergoing cardiopulmonary bypass surgery
No full text
Right coronary ostial aneurysm following a Bentall procedure.
No full textWe report a case of a 69-year-old female with a previous Bentall procedure who developed a right coronary ostial aneurysm. The aneurysm was excluded with a Dacron patch and the right internal mammary artery was used to restore flow to the coronary artery
Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study.
No full textEndothelial progenitor cells (EPCs) are a subtype of hematopoietic stem cells, which contribute to the repair of injured endothelium. Treatment with atorvastatin has been shown to increase EPC count in patients with coronary artery disease. Therefore, we investigated whether atorvastatin augments the number of EPCs after cardiopulmonary bypass (CPB) surgery. We conducted a randomized double-blind, placebo-controlled, 2-way crossover trial in 50 patients undergoing elective coronary surgery. Patients received either 3-week treatment with atorvastatin or placebo. EPCs were quantitated by flow cytometric phenotyping on blood samples. Levels of interleukin, IL-6 and IL-8; tumor necrosis factor alpha; SDF-1alpha; granulocyte colony-stimulating factor; and vascular endothelial growth factor were determined at recruitment, preoperatively, post-CPB, and 6, 12, and 24 hours postoperatively. The atorvastatin group showed a significantly higher amount of EPCs both pre- and postoperatively compared with the placebo, with a >4-fold increase compared with the baseline values. CPB induced an increase in all cytokines, but the levels of proinflammatory cytokines were significantly lower in the atorvastatin group (P < 0.05). Statin did not affect levels of SDF-1alpha, granulocyte colony-stimulating factor, and vascular endothelial growth factor. However, no correlation was found between plasma levels of any cytokine and number of EPCs, with the exception of SDF-1alpha. Pretreatment with atorvastatin significantly increases the amount of EPCs after CPB, by a mechanism independent of plasma levels of cytokines and cholesterol
Predictive factors of long-term results following valve repair in ischemic mitral valve prolapse
No full textIncrease in circulating endothelial progenitor cells by atorvastatin treatment in patients undergoing cardiopulmonary bypass surgery
No full textReduction by Indobufen of Neutrophil Activation in Peripheral Arterial Occlusive Disease
No full textWe evaluated the effectiveness of indobufen administration in reducing neutrophil activation in a clinical model of ischemia-reperfusion. Thirty stable patients with intermittent claudication due to occlusive peripheral arterial disease of the leg were randomly assigned to two groups. Patients in group I were treated with indobufen [200 mg orally twice daily (p.o. b.i.d.) for a week]; patients in group II received a placebo. Both groups of patients were submitted to standardized treadmill exercise until onset of claudication. Plasma levels of thromboxane B2 (TxB2) and 6-keto-prostaglandin F1alpha(6-k-PGF1alpha) neutrophil filterability, and neutrophil activation (by nitro-blue tetrazolium test) were assessed in blood samples from the femoral vein draining the ischemic leg. The values were obtained at rest and 5, 30, and 60 min after onset of claudication. Urinary albumin excretion was measured at rest and 1 h after onset of claudication. Plasma levels of TxB2 and 6-k-PGF1alpha increased significantly in the placebo group 5 min after onset of claudication, whereas only a slight nonsignificant increase was observed in the indobufen-treated group at the same timepoint
Symptomatic unstable aortic hematoma: a case report.
No full textA 69-year-old woman was admitted to our institution complaining of dyspnoea, retrosternal burning and asthenia. Medical history included a traumatic left clavicle fracture occurred two years months before. Physical examination, electrocardiogram and myocardial enzymes were normal. The patient underwent a contrast CT scan which evidenced an hematoma of thoracic aorta. The aorta was dilated from the origin of left subclavian artery as far as 75 mm of descending aorta, with a maximum diameter of 48 mm. The extimated wall thickness was 20 mm. Because of the worsening of symptoms and hypotension, a second CT scan was done, which showed an area of increased contrast agent capturing, suggestive of an incipient aortic rupture. The patient was referred to urgent endovascular repair.
An endoprosthesis Valiant Thoracic Medtronic was positioned starting from the left subclavian artery up to descending aorta. Aortic angiogram performed before discharge showed correct position without endoleaks. The patient was discharged in good general condition two days later.
In conclusions, in a clinical setting of chronic peri-aortic hematoma, the ingravescence of symptoms represents a strong indication for prompt endovascular treatment
Transcatheter Technologies for Valvular Replacement: an Update
No full textThis report provides a brief overview of the basic principles, recent advances, and recommendations for the treatment of severe aortic stenosis with transcatheter aortic valve replacement (TAVR) in adults. Approaches that avoid neurological, cardiac and peripheral vascular complications have been developed. In addition, TAVR can be performed in intermediate- and low-risk patients. However, these procedures require specialized training and may not allow for complete resolution of the underlying issue. Even if cardiologists learn to perform the procedure and despite advancements in device technology, TAVR is still susceptible to structural valve degeneration, thrombosis and late cerebral embolization. To date, TAVR has shown no consistent advantage over surgical aortic valve replacement (SAVR) in intermediate- and low-risk patients
- …
